Trial · NCT04652102
Results by group138
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 138
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Experienced a First Episode of Virologically-confirmed {Reverse Transcription Polymerase Chain Reaction (RT-PCR) Positive} Case of COVID-19 of Any Severity | CVnCoV 12 μg Vaccine | 83 | Participants | ||
| Number of Participants Who Experienced a First Episode of Virologically-confirmed {Reverse Transcription Polymerase Chain Reaction (RT-PCR) Positive} Case of COVID-19 of Any Severity | Placebo | 145 | Participants | ||
| Number of Participants Who Experienced One or More Medically-attended Adverse Events (AE) | CVnCoV 12 μg Vaccine | Any Medically-attended AE | 2555 | Participants | |
| Number of Participants Who Experienced One or More Medically-attended Adverse Events (AE) | Placebo | Any Medically-attended AE | 2084 | Participants | |
| Number of Participants Who Experienced One or More Medically-attended Adverse Events (AE) | CVnCoV 12 μg Vaccine | Any Related Medically-attended AE | 505 | Participants | |
| Number of Participants Who Experienced One or More Medically-attended Adverse Events (AE) | Placebo | Any Related Medically-attended AE | 138 | Participants | |
| Number of Participants Who Experienced One or More Serious AE (SAE) | CVnCoV 12 μg Vaccine | Any SAE | 149 | Participants | |
| Number of Participants Who Experienced One or More Serious AE (SAE) | Placebo | Any SAE | 111 | Participants | |
| Number of Participants Who Experienced One or More Serious AE (SAE) | CVnCoV 12 μg Vaccine | Any Related SAE | 8 | Participants | |
| Number of Participants Who Experienced One or More Serious AE (SAE) | Placebo | Any Related SAE | 1 | Participants | |
| Intensity of SAEs as Per Investigator Assessment | CVnCoV 12 μg Vaccine | Mild (Grade 1) | 21 | Participants | |
| Intensity of SAEs as Per Investigator Assessment | Placebo | Mild (Grade 1) | 10 | Participants | |
| Intensity of SAEs as Per Investigator Assessment | CVnCoV 12 μg Vaccine | Moderate (Grade 2) | 50 | Participants | |
| Intensity of SAEs as Per Investigator Assessment | Placebo | Moderate (Grade 2) | 35 | Participants | |
| Intensity of SAEs as Per Investigator Assessment | CVnCoV 12 μg Vaccine | Severe (Grade 3) | 74 | Participants | |
| Intensity of SAEs as Per Investigator Assessment | Placebo | Severe (Grade 3) | 66 | Participants | |
| Intensity of SAEs as Per Investigator Assessment | CVnCoV 12 μg Vaccine | Missing | 4 | Participants | |
| Intensity of SAEs as Per Investigator Assessment | Placebo | Missing | 0 | Participants | |
| Number of Participants Who Experienced One or More Adverse Event of Special Interest (AESI) | CVnCoV 12 μg Vaccine | Any AESI | 64 | Participants | |
| Number of Participants Who Experienced One or More Adverse Event of Special Interest (AESI) | Placebo | Any AESI | 47 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04652102/results